血清白细胞介素-35水平与急性运动轴索型神经病患者疾病严重程度的关系

The study on the relationship between serum level of interleukin-35 and disease severity of acute motor axonal neuropathy

目的探讨白细胞介素-35(IL-35)在急性运动轴索型神经病(AMAN)发病中的意义,以及其与疾病严重程度和预后的相关性。方法 30例急性期患者(AMAN组)入院2周时采用GBS运动功能缺损评分(GDS)评估患者的疾病严重程度,采用Erasmus吉兰-巴雷综合征预后评分(EGOS)评估患者6个月预后;另取30例健康志愿者作为对照(HCs组)。用酶联免疫吸附测定法(ELISA)检测2组IL-35水平,并分析AMAN患者血清IL-35水平与疾病严重程度及预后的相关性。依标准品对IL-35检测限度将AMAN患者分为低分泌组(<0.13μg/L)和分泌组(≥0.13μg/L),比较2组GDS和EGOS水平差异。结果 AMAN组血清IL-35水平较HCs组明显降低,且AMAN患者急性期血清IL-35水平与GDS和EGOS呈负相关(rs分别为-0.430和-0.523,均P<0.05),低分泌组(17例)的GDS和EGOS均高于分泌组(13例)。结论 IL-35可能参与了AMAN的发病过程,且作为一个保护性细胞因子,血清IL-35的水平有望作为评估患者病情严重程度和预后的重要生物学标志物。

Objective To investigate the significance of interleukin-35(IL-35)level in patients with acute motor axonal neuropathy(AMAN)and explore the correlation of the serum IL-35 level with disease severity and prognosis.Methods The GBS disability score(GDS)was used to assess the disease severity at 2 weeks after admission in 30 patients with AMAN(group AMAN).Erasmus GBS outcome score(EGOS)was used to evaluate the prognosis of patients in 6 months.Thirty healthy volunteers was used as control group(group HCs).Serum concentration levels of IL-35 were measured by enzyme-linked immunosorbent assay(ELISA).The correlation of the serum level of IL-35 with disease severity and prognosis in AMAN patients was analyzed.According to the standard of IL-35 detection,AMAN patients were subdivided into low secretory group(<0.13μg/L)and secretory group(≥0.13μg/L),and GDS and EGOS levels were compared between the two groups.Results The serum level of IL-35 was significantly lower in group AMAN than that in group HCs.The serum level of IL-35 was negatively correlated with GDS and EGOS(rs=-0.430 and-0.523,P<0.05).Values of GDS and EGOS were higher in low secretory group than those in the secretory group.Conclusion The serum level of IL-35 may participate in the pathogenic process of AMAN.As a protective cytokine,the serum level of IL-35 can be used as an important biomarker for the severity and outcomes of AMAN.